Table 2. Characteristics of study subjects in gender.
| Variable | Total | Male | Female |
|---|---|---|---|
| N | 57 | 39 | 18 |
| Age at transplantation, year | 32.0(25.0–36.0) | 33.0(25.0–36.0) | 30.0(26.0–38.0) |
| HLA mismatches, median (range) | |||
| HLA-A/B | 2(0–4) | 2(0–4) | 2(0–4) |
| HLA-DR | 1(0–2) | 1(0–2) | 0(0–2) |
| Time after Tx, month | 257(188–333) | 257(205–351) | 219(163–307)* |
| Body mass index (BMI) | 21.2(19.1–22.9) | 21.3(19.3–23.8) | 20.3(18.9–22.2) |
| Blood pressure, mmHg | |||
| Systolic | 126(120–132) | 126(120–132) | 123(112–128) |
| Diastolic | 76(70–84) | 76(70–84) | 74(70–80) |
| eGFR at 2004 (ml/min) | 55.2(43.5–68.6) | 56.4(46.4–70.4) | 50.1(40.5–59.3) |
| eGFR at 2008 (ml/min) | 47.7(37.8–57.8) | 48.0(38.9–60.6) | 43.1(36.8–56.7) |
| eGFR at 2012 (ml/min) | 44.8(32.5–58.5) | 44.9(32.9–63.9) | 41.8(31.0–56.3) |
| ΔeGFR(ml/min) | -2.8(-7.9–1.4) | -2.8(-5.5–2.7) | -2.4(-9.1–0.5) |
| Blood glucose (mg/dl) | 101.0(90.8–117.5) | 108.0(96.0–128.8) | 93.0(84.0–100.0) |
| LDL-C mg/dl | 104.0(86.8–123.5) | 113.0(95.3–128.3) | 90.5(82.0–104.0)* |
| HDL-C mg/dl | 63.0(53.0–81.8) | 59.0(52.0–71.3) | 76.0(59.0–92.0)* |
| LDL-C/HDL-C ratio | 1.7(1.19–2.15) | 1.90(1.47–2.25) | 1.23(1.00–1.63)** |
| Triglyceride | 146.0(101.8–208.5) | 146.0(99.8–216.0) | 162.5(112.0–196.0) |
| Total ADPN at 2012 (μg/ml) | 10.1(6.5–14.9) | 8.8(5.9–14.3) | 11.9(8.2–17.2) |
| HMW ADPN(μg/ml) | 3.8(1.7–6.9) | 3.3(1.4–6.5) | 5.8(2.9–7.7) |
| MMW ADPN(μg/ml) | 1.5(1.0–2.6) | 1.5(0.9–2.4) | 1.7(1.4–3.1) |
| LMW ADPN(μg/ml) | 4.3(3.2–5.3) | 4.3(3.2–5.0) | 4.4(2.9–6.2) |
| HMW ADPN ratio(%) | 40.6(29.1–48.1) | 38.4(24.6–46.8) | 45.7(39.6–48.5) |
| LMW ADPN ratio(%) | 42.5(34.9–51.9) | 45.1(37.9–55.5) | 37.6(31.5–42.5) |
| Visceral fat area (cm2) | 88.1(60.6–137.1) | 106.6(66.3–165.9) | 80.2(58.5–104.4) |
| Subcutaneous fat area (cm2) | 94.9(61.9–131.7) | 85.1(53.7–121.1) | 118.5(88.7–141.4)* |
| Therapeutic agents (Drug use, %) | |||
| Immunosuppressive drugs | |||
| Steroids | 57(100%) | 39(100%) | 18(100%) |
| Antimetabolites | 54(95%) | 37(94%) | 17(94%) |
| Calcineurin inhibitors | 41(72%) | 26(67%) | 15(83%) |
| Antihypertensive drugs | |||
| ACEi/ARB | 51(82%) | 35(89%) | 13(72%) |
| Antidiabetic drugs | 27(48%) | 19(49%) | 8(44%) |
| Insulin | 1(2%) | 1(2.4%) | 0(0%) |
| Oral antidiabetic drugs | 8(13%) | 6(15%) | 2(11%) |
| Statins | 33(58%) | 22(56%) | 11(61%) |
Value are shown as the Median (IQR) *<0.05, **<0.01.